JV_Logo_H_RGB-L-1607.png
JenaValve Appoints Duane Pinto, MD, MPH, as Chief Medical Officer
October 24, 2022 09:00 ET | JenaValve Technology, Inc.
IRVINE, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that...
JV_Logo_H_RGB-L-1607.png
JenaValve Completes Enrollment in the ALIGN-AR IDE Clinical Trial
September 14, 2022 06:00 ET | JenaValve Technology, Inc.
IRVINE, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the...
JV_Logo_H_RGB-L-1607.png
JenaValve Raises $100 Million to Advance Trilogy TAVR Solution
August 31, 2022 06:00 ET | JenaValve Technology, Inc.
IRVINE, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc. (“JenaValve or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR)...
JV_Logo_H_RGB-L-1607.png
JenaValve Announces Results from First Commercial Trilogy Heart Valve System Implants in Europe
June 28, 2022 08:00 ET | JenaValve Technology, Inc.
IRVINE, Calif., June 28, 2022 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc. (“JenaValve” or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement...
JV_Logo_H_RGB-L-1607.png
JenaValve Appoints Kari Moore as Chief Financial Officer
May 17, 2022 08:00 ET | JenaValve Technology, Inc.
IRVINE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc. (“JenaValve or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR)...
JV_Logo_H_RGB-L-1607.png
JenaValve Announces Strategic Investment and Licensing Agreement with Peijia Medical Limited
January 18, 2022 16:04 ET | JenaValve Technology, Inc.
IRVINE, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc. (“JenaValve” or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement...
JV_Logo_H_RGB-L-1607.png
JenaValve Announces First European Commercial Implants with the Trilogy™ Heart Valve System
October 18, 2021 16:03 ET | JenaValve Technology, Inc.
IRVINE, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the...
JV_Logo_H_RGB-L-1607.png
JenaValve gibt erste kommerzielle Implantationen des Trilogy™-Herzklappensystems in Europa bekannt
October 18, 2021 16:03 ET | JenaValve Technology, Inc.
IRVINE, Kalifornien, Oct. 18, 2021 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., Entwickler und Hersteller von differenzierten Transkatheter-Aortenklappenimplantationssystemen (TAVI) (auch als...
JV_Logo_H_RGB-L-1607.png
JenaValve Receives IDE Approval to Initiate The ALIGN-AR Pivotal PMA Trial
August 16, 2021 07:00 ET | JenaValve Technology, Inc.
IRVINE, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer, and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced FDA...
JV_Logo_H_RGB-L-1607.png
Establishing TAVR for the Treatment of Aortic Regurgitation(1)
June 15, 2021 07:05 ET | JenaValve Technology, Inc.
IRVINE, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer, and manufacturer of a novel transcatheter aortic valve replacement (TAVR) system, is pleased to announce...